Revenue Recognition - Disaggregation of Revenue (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Disaggregation of Revenue [Line Items]
Total revenues	$ 104,754	$ 69,056	$ 68,458
Americas
Disaggregation of Revenue [Line Items]
Total revenues	23,481	24,352	13,039
EMEA
Disaggregation of Revenue [Line Items]
Total revenues	20,187	19,257	37,133
APAC
Disaggregation of Revenue [Line Items]
Total revenues	61,086	25,447	18,286
Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	70,657	30,220	29,465
Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	34,097	38,836	38,993
Performance Enzymes
Disaggregation of Revenue [Line Items]
Total revenues	90,515	48,106	58,156
Performance Enzymes | Americas
Disaggregation of Revenue [Line Items]
Total revenues	16,114	11,111	13,039
Performance Enzymes | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	13,315	11,548	26,831
Performance Enzymes | APAC
Disaggregation of Revenue [Line Items]
Total revenues	61,086	25,447	18,286
Performance Enzymes | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	70,657	30,220	29,465
Performance Enzymes | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	19,858	17,886	28,691
Novel Biotherapeutics
Disaggregation of Revenue [Line Items]
Total revenues	14,239	20,950	10,302
Novel Biotherapeutics | Americas
Disaggregation of Revenue [Line Items]
Total revenues	7,367	13,241	0
Novel Biotherapeutics | EMEA
Disaggregation of Revenue [Line Items]
Total revenues	6,872	7,709	10,302
Novel Biotherapeutics | APAC
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0
Novel Biotherapeutics | Product revenue
Disaggregation of Revenue [Line Items]
Total revenues	0	0	0
Novel Biotherapeutics | Research and development revenue
Disaggregation of Revenue [Line Items]
Total revenues	$ 14,239	$ 20,950	$ 10,302